TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29175067
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol (528 women)
Study: 29175067
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist protocol (495 women)
Study: 22388491
Drug: Caffeine supplementation
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplementation (doses of 2, 4, 6, 8, and 10 mg·kg bm(‐1))
Study: 18508290
Drug: Satavaptan 5
Normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satavaptan 5 mg once daily
Study: 18508290
Drug: Satavaptan 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satavaptan 12.5 mg once daily
Study: 18508290
Drug: Satavaptan 25
Normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satavaptan 25 mg once daily
Study: 17262795
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate at a dose of 440 mg/m²/day for 28 days
Study: 10770462
Drug: Lorazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.5 mg twice daily)
Study: 10163609
Drug: Metered-Dose Inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-Dose Inhaler (MDI)
Study: 16388832
Drug: Hydrocortisone 100
Normalized name: hydrocortisone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 100 mg
Study: 22051940
Drug: Basic Plus
Normalized name: Casanthranol/Docusate Sodium 30 MG-100 MG Oral Capsule, Liquid Filled [LAXA-BASIC PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic Plus (n = 137) - PCP counseling every 4 months plus monthly LC visits during the first year of treatment
Study: 20613460
Drug: Salsalate (anti-inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (anti-inflammatory treatment)
Study: 17663101
Drug: Acupoint-injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint-injection of BCG polysaccharide nuclear acid (BCG-PSN)
Study: 17663101
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of BCG-PSN
Study: 17663101
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of interferon
Study: 17663101
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (blank control group)
Study: 16105152
Drug: Sotalol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 100 mg
Study: 16105152
Drug: Lignocaine 100
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 100 mg
Study: 12139216
Drug: Nitazoxanide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (200 mg for 3 days)
Study: 12139216
Drug: Quinfamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinfamide (100 mg for 1 day), mebendazole (200 mg for 3 days), or both
Study: 10199534
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg) before cardiopulmonary bypass and before declamping of the aorta (MPS group, n = 11)
Study: 437665
Drug: Actovegin forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin forte dragées, 2 dragées three times daily for six weeks
Study: 30597025
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rifampicin (35 mg/kg)
Study: 30597025
Drug: Standard rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rifampicin (10 mg/kg daily)
Study: 14600809
Drug: Heparin anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin anticoagulation
Study: 16882889
Drug: Eccentric strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eccentric strength training (squats on a 25 degrees decline board, 3 sets of 15 repetitions, twice daily for 12 weeks)
Study: 16882889
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (open patellar tenotomy with rehabilitation)
Study: 11748758
Drug: acute levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: acute levodopa (L-dopa) challenge
Study: 9269364
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg suppository diclofenac before surgical incision and morphine infusion 1.5 mg per hour postoperatively
Study: 9269364
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion 1.5 mg per hour postoperatively
Study: 8111804
Drug: Diltiazem 90
Normalized name: diltiazem 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 90 mg BID
Study: 8111804
Drug: Diltiazem 180
Normalized name: diltiazem 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 180 mg BID
Study: 27100753
Drug: 450 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 cc blood donation
Study: 24026316
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of methylprednisolone
Study: 24026316
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of methylprednisolone
Study: 18042410
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ASU
Study: 11834948
Drug: Genotypic resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotypic resistance information (G)
Study: 7570257
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Laser and Ultrasounds
Study: 2287048
Drug: Non-supervised home
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-supervised home exercise program (2 km walk-jog exercise daily for 1 month, HR at 90-100% of anaerobic threshold)
Study: 10782805
Drug: Infliximab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (10 mg/kg)
Study: 30840903
Drug: Second intravenous
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second intravenous immunoglobulin (IVIG) (2 g/kg)
Study: 30927252
Drug: HIV-positive children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-positive children on antiretroviral therapy (ART)
Study: 30927252
Drug: HIV-positive children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-positive children with nevirapine treatment
Study: 27859546
Drug: Bimekizumab (8-640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab (8-640 mg)
Study: 27859546
Drug: Bimekizumab (160-640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab (160-640 mg)
Study: 27859546
Drug: Bimekizumab (≥160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab (≥160 mg)
Study: 23867729
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) injections
Study: 12753335
Drug: IFN/Riba and
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN/Riba and amantadine (Ama) including a 2‐week initial high IFN induction course (18 MU IFN daily) (group A)
Study: 8511862
Drug: Cryotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy (CT) in combination with therapeutic exercise
Study: 8511862
Drug: Cryoelectrotherapy (CET)
Normalized name: CET
DrugBank: Cefalotin (DB00456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cryoelectrotherapy (CET) in combination with therapeutic exercise
Study: 27613466
Drug: S0597 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: S0597 50 μg
Study: 27613466
Drug: S0597 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: S0597 200 μg
Study: 27613466
Drug: S0597 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: S0597 400 μg
Study: 18155534
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (EPO) dose
Study: 16846409
Drug: Aprotinin (500,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (500,000 KIU) administered in two equal doses (before skin incision and added to the pump prime)
Study: 12848279
Drug: n-3 FA
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 FA (fermented soybean milk with fish oil containing 600 mg of EPA and 260 mg of DHA/d for 12 weeks)
Study: 9738550
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (delayed-treatment)
Study: 21602313
Drug: Metreleptin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (10 mg/day self-injected s.c.)
Study: 7650958
Drug: Electric acupuncture
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric acupuncture treatment
Study: 7650958
Drug: Supportive medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive medication (Control)
Study: 25682232
Drug: Tiotropium 2.5
Normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 2.5 μg
Study: 25694383
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist treatment (goserelin, 3.6 mg) starting 3-5 days postoperatively (Group O)
Study: 25694383
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist treatment (goserelin, 3.6 mg) starting on days 1-5 of menstruation (Group M)
Study: 25694383
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist treatment (Group M)
Study: 25694383
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist treatment (Group O)
Study: 19889154
Drug: Cyclic photodynamic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic photodynamic therapy (PDT) treatments at 4- to 8-week intervals for 2 years.
Study: 18594748
Drug: Crenotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenotherapy treatment (vapour inhalation, aerosol and nasal douching) with thermal water for 14 days
Study: 18594748
Drug: Nasal douching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal douching and aerosol with saline twice a day for 14 days
Study: 18594748
Drug: Crenotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenotherapy treatment with thermal water
Study: 12885707
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) from limeade, 25 mg consumed with each of 2 daily meals, 500 mL limeade twice a day, 6 days/week for 8 months
Study: 8630579
Drug: 1,000 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 micrograms of inhaled beclomethasone daily for 1 yr
Study: 21107432
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg/Amlodipine 5 mg
Study: 21107432
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg/Hydrochlorothiazide 12.5 mg
Study: 17439538
Drug: Diazepam 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 30 mg intrarectal gel
Study: 10691230
Drug: PCA (patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA (patient-controlled analgesia) with intravenous morphine
Study: 8458180
Drug: 5 x
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x 2.5 mg levoleucovorin tablets
Study: 8458180
Drug: 5 x
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x 5 mg leucovorin tablets
Study: 8458180
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 12.5 mg levoleucovorin tablet
Study: 8458180
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 25 mg leucovorin tablet
Study: 8458180
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg levoleucovorin injection
Study: 8458180
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 7.5 mg levoleucovorin tablets
Study: 8458180
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg leucovorin injection
Study: 8458180
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 15 mg leucovorin tablets
Study: 26104969
Drug: β-blocker bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker bisoprolol 5mg qd
Study: 27774730
Drug: In-center daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-center daily hemodialysis (6 days/week)
Study: 18362486
Drug: Fluoxetine 90
Normalized name: fluoxetine 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 90 mg plus Tadalafil 20 mg
Study: 18362486
Drug: Fluoxetine 90
Normalized name: fluoxetine 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 90 mg
Study: 15809403
Drug: Haloperidol (2-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2-20 mg/d)
Study: 10216796
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure control and angiotensin-converting enzyme (ACE) inhibitors
Study: 10216796
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hyperlipidemia
Study: 431401
Drug: C+G (Carbenicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+G (Carbenicillin + Gentamicin)
Study: 431401
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (C+A, C+G, C+S)
Study: 29749328
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E (400 mg/day)
Study: 29749328
Drug: Oral UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral UDCA (15 mg/kg/day)
Study: 29749328
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin E and UDCA
Study: 29749328
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug except chemotherapy)
Study: 22252804
Drug: Dihydroartemisinin-piperaquine monthly
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine monthly (DPm)
Study: 15653941
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg‐60 mg/day)
Study: 9818845
Drug: Diastat (diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diastat (diazepam rectal gel)
Study: 7656471
Drug: L-fucose in
Normalized name: L-FUCOSE
DrugBank: Fucose (DB15236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-fucose in RA patients
Study: 786422
Drug: Flurbiprofen 150
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 150 mg daily for 5 days
Study: 786422
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin 3.6 g daily for 5 days
Study: 6773484
Drug: Parenteral amino
Normalized name: parenteral amino acid 7 % comb no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral amino acids
Study: 22215654
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (delivered intragastrically)
Study: 16079222
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion (3 kcal/min)
Study: 21284343
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of arginine (20 g per day)
Study: 16274036
Drug: Perioperative nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative nutrition support (enteral and parenteral nutrition)
Study: 16274036
Drug: Routine postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine postoperative parenteral nutrition
Study: 16274036
Drug: Perioperative nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative nutrition support (enteral and parenteral nutrition) in PD subgroup
Study: 16274036
Drug: Routine postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine postoperative parenteral nutrition in PD subgroup
Study: 11964588
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg/kg-1 after induction of anesthesia
Study: 9466469
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg orally, 12 and 2 hours before ischemia)
Study: 9466469
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg orally, 2 hours before ischemia)
Study: 2649141
Drug: Mild induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild induction and intensive consolidation therapy
Study: 2649141
Drug: Mild post
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild post consolidation treatment
Study: 2649141
Drug: CNS prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS prophylaxis with intrathecal chemotherapy and intermediate dose i.v. methotrexate (MTX) and cytosine arabinoside (ARA-C)
Study: 333515
Drug: Oral prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prostaglandin E2 (10 tablets given on an hourly regime)
Study: 31067324
Drug: QH treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: QH treatments in specialist orthodontic clinics (QHS)
Study: 31067324
Drug: QH treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: QH treatments in general dentistry (QHG)
Study: 31067324
Drug: EP treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP treatments in specialist orthodontic clinics (EPS)
Study: 31067324
Drug: EP treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP treatments in general dentistry (EPG)
Study: 27740929
Drug: 11.25- or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25- or 30-mg 3-month leuprolide acetate (LA)
Study: 27740929
Drug: 3-month leuprolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-month leuprolide acetate treatments
Study: 27740929
Drug: Basal LH
Normalized name: LH-708
DrugBank: LH-708 (DB17636)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal LH < 0.60 IU/L
Study: 19327317
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (group 2)
Study: 22584353
Drug: Valacyclovir (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (2 g q.i.d.)
Study: 17973956
Drug: Valganciclovir (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (900 mg b.i.d. for a minimum of 14 days)
Study: 12965978
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole infusion plus endoscopic therapy
Study: 12965978
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole infusion alone
Study: 2140382
Drug: Paroxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (30 mg/day)
Study: 2198001
Drug: Breast conservation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conservation therapy
Study: 3887560
Drug: Cefadroxil 1
Normalized name: CEFADROXIL 1GM TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 1 g once daily for 3 days
Study: 3887560
Drug: Cefadroxil 1
Normalized name: CEFADROXIL 1GM TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 1 g once daily for 7 days
Study: 3887560
Drug: Amoxycillin 375
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 375 mg t.i.d. for 7 days
Study: 28668204
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2, day 1) and Pemetrexed (500 mg/m2, day 1)
Study: 28668204
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2, day 1) and Vinorelbine (25 mg/m2, days 1 and 8)
Study: 22706833
Drug: Telephone-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered cognitive behavioral therapy (T-CBT)
Study: 24447003
Drug: Face-to-face cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive behavioral therapy (FtF-CBT)
Study: 18616811
Drug: Single-dose pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-dose pegfilgrastim 6 mg
Study: 18616811
Drug: Daily filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily filgrastim 5 mug/kg
Study: 15960931
Drug: Samarium-153 (Quadramet)
Normalized name: Samarium 153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samarium-153 (Quadramet) therapy
Study: 12610039
Drug: Acute administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute administration of GLP-1
Study: 2066762
Drug: Carboplatin 200
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 200 mg/mq, doxorubicin 45 mg/mq, and cyclophosphamide 600 mg/mq (CAC)